Taligen is at the forefront of developing targeted therapies that regulate the complement system to treat inflammatory and immune diseases in a whole new way.

Based on unique insights and proprietary technology, Taligen’s novel biologic drugs intervene at key points in the complement system, a potent and ubiquitous immune pathway that, in the past, has been difficult to effectively regulate … until now.

Taligen’s proprietary platform enables the development of therapeutics which selectively identify and are precisely directed to the cell surface of inflammatory tissues where they naturally and broadly control inflammation.

LATEST NEWS

August, 2010 - Taligen Therapeutics announces that data on three of Taligen's pipeline drugs will be highlighted at the XXIII International Complement Workshop.

June, 2010 - Taligen Therapeutics receives Biotechnology Company of the Year Award from University of Colorado and Michael Holers honored with Lifetime Achievement Award

April, 2010 - Taligen Therapeutics announces the appointment of John Maraganore, PhD to its Board of Directors

April, 2010 - Taligen Therapeutics announces the addition of Bill Lundberg, MD as Chief Medical Officer and Karen Tubridy, PharmD as Vice President, Clinical Operations and Regulatory Affairs

More News...

Taligen Fact Sheet